Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas
In 2012, the FDA approved vismodegib (Erivedge Genentech, Inc.) for locally advanced basal cell carcinoma (BCC) in addition to other indications. Hedgehog pathway inhibitors have been used as sole therapy as well as adjuvant and neoadjuvant treatment, before definitive surgical management. In the following cases, we describe the utility of surgically debulking large exophytic BCCs before hedgehog pathway inhibitor use to hasten response to the hedgehog inhibitor, decrease duration of therapy, minimize side effects, and potentially decrease recurrence.
Files
-
View: Sonic_Hedgehog_Pathway_Blockade_After_Surgical_Debulk_of_Large_Exophytic_Basal_Cell_Carcinomas.pdf
Download: Sonic_Hedgehog_Pathway_Blockade_After_Surgical_Debulk_of_Large_Exophytic_Basal_Cell_Carcinomas.pdf
Metadata
Work Title Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas Access Creators - Paul J. Wirth
- Ryan Hobbs
- Elizabeth Billingsley
- Allison T. Vidimos
- Charlene Lam
License In Copyright (Rights Reserved) Work Type Article Publisher - Dermatologic Surgery
Publication Date June 7, 2021 Publisher Identifier (DOI) - https://doi.org/10.1097/DSS.0000000000002957
Deposited March 06, 2023 Versions
Analytics
Collections
This resource is currently not in any collection.
Work History
Version 1
published-
Created
-
Added
Sonic_Hedgehog_Pathway_Blockade_After_Surgical_Debulk_of_Large_Exophytic_Basal_Cell_Carcinomas.pdf -
Added Creator Paul J. Wirth
-
Added Creator Ryan Hobbs
-
Added Creator Elizabeth Billingsley
-
Added Creator Allison T. Vidimos
-
Added Creator Charlene Lam
-
Published
-
Updated Publisher, Publication Date Show ChangesPublisherPublication Date
Journal of Dermatologic Surgery and Oncology- Dermatologic Surgery
2021-08-01- 2021-06-07
-
Updated
